文献速递浆细胞疾病

多发性骨髓瘤患者骨髓中高谷氨酸水平促进破骨细胞形成:溶骨性骨病的新靶点

High glutamate levels in the bone marrow of multiple myeloma patients promote osteoclast formation: a novel target for osteolytic bone disease.
PubMed 文献 · Leukemia · 2025-07-28

多发性骨髓瘤(MM)是谷氨酰胺(Gln)依赖型肿瘤,其骨髓微环境中Gln较低而谷氨酸(Glu)较高。研究发现MM患者骨髓单核细胞释放的Glu高于意义未明的单克隆丙种球蛋白病(MGUS)或冒烟型多发性骨髓瘤(SMM)患者,且与骨吸收活性升高相关;Glu通过激活NF-κB-NFATc1通路刺激破骨细胞(OCL)分化,抑制Glu转运体EAAT1可阻碍OCL分化。提示靶向Glu转运可能成为预防MM溶骨性病变的新方法。

要点

  • MM患者骨髓单核细胞释放的Glu水平高于MGUS或SMM患者,且与骨吸收活性升高相关。
  • Glu通过激活NF-κB-NFATc1通路刺激破骨细胞分化。
  • 药理学抑制EAAT1通过阻断RANKL依赖性信号通路和肌动蛋白细胞骨架重组来阻碍破骨细胞分化。

核心结论

  • MM骨髓中高Glu水平参与破骨细胞形成,提示靶向Glu转运可能代表预防MM患者溶骨性病变的新方法。

研究设计与样本

  • 研究比较了MM患者与MGUS或SMM患者骨髓单核细胞释放Glu的水平及骨吸收活性,并探讨了Glu对破骨细胞分化的影响及EAAT1抑制作用。

主要发现

  • MM患者骨髓单核细胞释放的Glu水平高于MGUS或SMM患者,且Glu产生增加与骨吸收活性升高相关。
  • Glu在来自癌前病变患者的低Glu骨髓样本中通过激活NF-κB-NFATc1通路刺激破骨细胞分化,但在MM患者的高Glu样本中无此作用。
  • 破骨细胞形成的早期阶段与高细胞内Glu含量及Glu转运体EAAT1的诱导相关。
  • 药理学抑制EAAT1通过阻断RANKL依赖性信号通路和肌动蛋白细胞骨架重组来阻碍破骨细胞分化。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple Myeloma (MM) is a glutamine (Gln)-addicted cancer. Consequently, the MM bone microenvironment (BM) is characterized by lower Gln and higher glutamate (Glu) levels than those in pre-malignant monoclonal gammopathies. Such MM-dependent metabolic perturbation impairs osteoblast differentiation in the bone microenvironment, but its effect on osteoclast (OCL) bone resorption is still unknown. We first show that bone marrow mononuclear cells from MM patients release higher levels of Glu compared to those from patients with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). This increased Glu production correlates with elevated bone resorption activity. We then demonstrate that Glu stimulates OCL differentiation via the activation of NF-κB-NFATc1 pathway in low-Glu BM samples from pre-malignant patients but not in high-Glu samples of MM patients. Secondly, the early phase of OCL formation was associated with high Glu intracellular content and induction of the Glu transporter EAAT1. Consistently, the pharmacological inhibition of EAAT1 hinders OCL differentiation by blocking the RANKL-dependent signaling pathway and actin cytoskeleton reorganization. Overall, our data indicate that high Glu levels in MM bone marrow are involved in OCL formation, suggesting that targeting Glu transport may represent a novel approach for the prevention of osteolytic lesions in MM patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Toscani D, Lungu O, Chiu M, et al. High glutamate levels in the bone marrow of multiple myeloma patients promote osteoclast formation: a novel target for osteolytic bone disease. Leukemia. 2025. PMID: 40721650. doi:10.1038/s41375-025-02715-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。